Biopharma | Government | Foundations | Research Institutes


Bill & Melinda Gates Foundation — Advancing an mRNA-based antibody combination to help prevent HIV infection


“Moderna Therapeutics’ research has considerable potential for the development of an effective prevention intervention for HIV, and potentially other infectious diseases that disproportionately affect the world’s poorest people.” – Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation


Moderna is partnering with the Bill & Melinda Gates Foundation to develop an mRNA antibody program targeting human immunodeficiency virus (HIV) infection. The Gates Foundation committed up to $20 million in grant funding to support preclinical research as well as a first-in-human Phase 1 clinical study, and efforts to develop a novel, affordable combination of mRNA-based antibody therapeutics to combat this significant global health issue will be led by Valera, Moderna’s infectious disease-focused venture.

Moderna’s global health partnership with the Foundation may also include additional mRNA-based development projects for various infectious diseases, with total funding of up to $100 million, further expanding the potential of Moderna’s transformative mRNA platform to impact millions of lives.